Last reviewed · How we verify

30% Oxygen

Sixth Affiliated Hospital, Sun Yat-sen University · FDA-approved active Small molecule Quality 5/100

30% Oxygen, marketed by Sixth Affiliated Hospital, Sun Yat-sen University, holds a unique position in the medical oxygen therapy market. The key composition patent, set to expire in 2028, provides a significant barrier to entry for competitors. However, the lack of detailed clinical trial results and revenue data poses a primary risk, potentially limiting investor confidence and market expansion.

At a glance

Generic name30% Oxygen
Also known as30% O2
SponsorSixth Affiliated Hospital, Sun Yat-sen University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: